Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
MORRISTOWN, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference as follows:
| Date: | Tuesday, November 17, 2015 |
| Time: | 4:30 p.m. EST |
| Location: | The New York Palace, NYC |
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer spatel@pernixtx.com Lisa Wilson, 212-452-2793 In-Site Communications lwilson@insitecony.com Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Strategic Development mlambertson@pernixtx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
